Fibroblast growth factor receptor inhibitors, a type of drug previously studied in the context of cancer, shows promise in reducing inflammation and cell death in brain and nerve tissue samples infected with Borrelia burgdorferi.
Tulane University researchers have identified a promising new approach to treating persistent neurological symptoms associated with Lyme disease, offering hope to patients who suffer from long-term effects of the bacterial infection, even after antibiotic treatment. Their results were published in Frontiers in Immunology.
Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted through tick bites, can lead to a range of symptoms, including those affecting the central and peripheral nervous systems. While antibiotics can effectively clear the infection in most cases, a subset of patients continues to experience symptoms such as memory loss, fatigue, and pain—a condition often referred to as post-treatment Lyme disease syndrome.
Breakthrough in Treatment
Principal investigator Geetha Parthasarathy, PhD, an assistant professor of microbiology and immunology at the Tulane National Primate Research Center, has discovered that fibroblast growth factor receptor inhibitors, a type of drug previously studied in the context of cancer, can significantly reduce inflammation and cell death in brain and nerve tissue samples infected with Borrelia burgdorferi. This discovery suggests that targeting FGFR pathways may offer an exciting new therapeutic approach to addressing persistent neuroinflammation in patients with post-treatment Lyme disease syndrome.
“Our findings open the door to new research approaches that can help us support patients suffering from the lasting effects of Lyme disease,” Parthasarathy said. “By focusing on the underlying inflammation that contributes to these symptoms, we hope to develop treatments that can improve the quality of life for those affected by this debilitating condition.”
Implications for Future Treatment
Researchers treated nerve tissue with live or inactivated Borrelia burgdorferi, followed by an application of FGFR inhibitors. Study results revealed a significant reduction in both inflammatory markers and of cell death.
While further research is needed to translate these findings into clinical treatments, the study represents an important step forward in understanding and potentially managing the complex aftermath of Lyme disease.
Reference: “Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo” by Geetha Parthasarathy, 19 March 2024, Frontiers in Immunology.
DOI: 10.3389/fimmu.2024.1327416
This study was funded by the Bay Area Lyme Foundation and supported with resources from the Tulane National Primate Research Center base grant of the National Institutes of Health, P51 OD011104.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
1 Comment
There is controversy on this topic. I’m unconvinced regarding the cause of post-lyme symptoms. However, whether it’s persistent infection due to cysts, persisting remnants, or a septic arthritis, the controversy is irrelevant; patiets report these symptoms and they are measurable. I’m impressed the author Dr. Parthasarathy not only appreciated the seriousness of the condition, but seems to have found an effective treatment. I’m interested in her hypothesis on bacterial remnants causing the symptoms. I hope Tulane University and the Bay Area Lyme Foundation continue this research.